Summary
This is a Phase I open-label, multicenter study designed to evaluate the safety,
tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab
administered as a single agent or in combination with atezolizumab and/or daratumumab or
rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R
non-Hodgkin lymphoma (NHL).